TherapeuticsMD Inc
NASDAQ:TXMD
TherapeuticsMD Inc
Revenue
TherapeuticsMD Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
TherapeuticsMD Inc
NASDAQ:TXMD
|
Revenue
$1.3m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-17%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
TherapeuticsMD Inc
Revenue Breakdown
Breakdown by Geography
TherapeuticsMD Inc
Breakdown by Segments
TherapeuticsMD Inc
Total Revenue:
1.3m
USD
|
License:
1.3m
USD
|
See Also
What is TherapeuticsMD Inc's Revenue?
Revenue
1.3m
USD
Based on the financial report for Dec 31, 2023, TherapeuticsMD Inc's Revenue amounts to 1.3m USD.
What is TherapeuticsMD Inc's Revenue growth rate?
Revenue CAGR 10Y
-17%
Over the last year, the Revenue growth was -98%. The average annual Revenue growth rates for TherapeuticsMD Inc have been -73% over the past three years , -40% over the past five years , and -17% over the past ten years .